查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胜肽市场 - 全球市场规模、份额、趋势分析、机会、预测报告（2019-2029）
市场调查报告书
商品编码
1391804

胜肽市场 - 全球市场规模、份额、趋势分析、机会、预测报告（2019-2029）

Antimicrobial Peptides Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Ailments ; By Distribution Channel ; By Route of Administration ; By End Use ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 200 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球胜肽市场规模以5.54%的复合年增长率稳定成长，到2029年将达到75.6亿美元。

由于抗菌素抗药性、感染疾病的流行、医学和生物技术应用的扩大以及胜肽合成技术的进步，对替代抗生素的需求增加，全球胜肽市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2022 年全球胜肽市场规模将达到 54.7 亿美元。 BlueWeave预测，在2023-2029年的预测期内，全球胜肽市场规模将以5.54%的复合年增长率成长，并于2029年达到75.6亿美元。抗药性疾病的增加增加了对替代治疗药物的需求，例如胜肽，这些药物对抗药性细菌表现出良好的效果，是推动全球胜肽市场成长的关键因素之一。此外，胜肽生产和合成方法的改进降低了生产成本并使其更容易获得。研发成本的增加也导致了新的胜肽类药物的诞生，扩大了市场。随着人们对胜肽在一系列医疗和非医疗应用（包括食品保鲜和农业）中的益处的了解的增加，进一步推动了市场的扩张。

该报告的详细分析提供了有关全球胜肽市场的成长潜力、未来趋势和统计数据的资讯。它还重点关注推动市场总规模预测的因素。该报告致力于提供全球胜肽市场的最新技术趋势以及产业见解，帮助决策者做出策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球胜肽市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 感染疾病增加
      • 越来越多地使用胜肽作为治疗剂
      • 抗菌药物抗药性发生率上升
    • 抑制因素
      • 开发成本高
      • 稳定性和配方问题
    • 机会
      • 技术进步
      • 中心导管相关血流感染疾病的发生率增加
    • 任务
      • 监管挑战
      • 市场认知度有限
  • 科技进步/最新发展
  • 法律规范
  • 波特五力分析

第4章全球胜肽市场概况

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 副产品
      • 植物
      • 细菌
      • 动物
      • 昆虫
    • 按疾病分类
    • 按配销通路
    • 依给药途径
      • 局部的
      • 皮下的
      • 静脉
    • 按最终用途
      • 製药与医疗保健
      • 农业工业
      • 生物工程
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

第5章北美胜肽市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按疾病分类
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 美国
      • 加拿大

第6章欧洲胜肽市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按疾病分类
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第7章亚太胜肽市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按疾病分类
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

第8章拉丁美洲胜肽市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按疾病分类
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第9章中东及非洲胜肽市场

  • 市场规模及预测（2019-2029）
    • 按金额
  • 市场占有率及预测
    • 副产品
    • 按疾病分类
    • 按配销通路
    • 依给药途径
    • 按最终用途
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第10章竞争形势

  • 主要企业及其产品列表
  • 全球胜肽企业市场占有率分析（2022年）
  • 透过管理参数进行竞争基准化分析
  • 主要策略发展（合併、收购、合作伙伴关係等）

第11章COVID-19对全球胜肽市场的影响

第12章公司简介（公司简介、财务矩阵、竞争形势、关键人才、主要竞争、联络地址、策略展望、SWOT分析）

  • Eli Lilly and Company
  • Pfizer Inc.
  • GSK Group of Companies（US）
  • Novartis AG
  • EnBiotix Inc.
  • Johnson &Johnson Private Limited
  • Merck &Co., Inc.
  • Alexion Pharmaceuticals, Inc.
  • Melinta Therapeutics, LLC
  • Vertex Pharmaceuticals Incorporated
  • AnaSpec
  • AMP Biotech
  • Phoenix Biotechnology Inc.
  • Novabiotics
  • Ontores Biotechnologies Inc.
  • 其他主要企业

第13章主要战略建议

第14章调查方法

简介目录
Product Code: BWC23959

Global Antimicrobial Peptides Market Size Set to Grow at Steady CAGR of 5.54% Reaching USD 7.56 Billion by 2029.

Global antimicrobial peptides market is flourishing due to an increasing demand for alternative antibiotics due to antimicrobial resistance, the rising prevalence of infectious diseases, expanding applications in pharmaceuticals and biotechnology, and advancements in peptide synthesis technologies.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global antimicrobial peptides market size at USD 5.47 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global antimicrobial peptides market size to grow at a CAGR of 5.54% reaching a value of USD 7.56 billion by 2029. The rising incidence of drug-resistant illnesses spurred the desire for alternative therapeutics, such as antimicrobial peptides, which exhibit promising efficacy against resistant bacteria and are one of the major reasons driving the growth of the global antimicrobial peptides market. Also, improvements in peptide manufacturing and synthesis methods lowered production costs and increased accessibility. Increasing research and development spending also resulted in the creation of new peptide-based medicines, which expanded the market. The market expansion is further fueled by growing knowledge of the advantages of antimicrobial peptides in a range of medical and non-medical uses, including food preservation and agriculture.

Antimicrobial Peptides - Overview

Antimicrobial peptides (AMPs) are naturally occurring tiny compounds present in a wide range of organisms, including people, plants, and animals. They are essential in innate immunity, as they protect against microbial infections. The antimicrobial activity of AMPs is broad-spectrum, targeting bacteria, fungi, viruses, and even some parasites. Their distinct method of action involves breaking microbial membranes, resulting in cell death, and they are resistant to resistance formation. AMPs have sparked attention in the fight against antibiotic-resistant bacteria and other infectious disorders due to their potential therapeutic applications. However, there are still issues in optimizing their stability and bioavailability for therapeutic usage, necessitating continuous study.

Impact of COVID-19 on Global Antimicrobial Peptides Market

The COVID-19 pandemic significantly impacted the global antimicrobial peptides market, causing a dynamic shift in demand and supply chains. With heightened awareness of infection prevention and treatment, the market witnessed accelerated research and development, driving innovation and adoption of antimicrobial peptides as potential therapeutic agents against the virus. However, disruptions in manufacturing, logistical challenges, and resource reallocation to combat the pandemic resulted in temporary setbacks for some market players. Despite these challenges, the pandemic underscored the importance of antimicrobial peptides, prompting increased investments and collaborations for developing robust antimicrobial solutions, and fostering long-term growth prospects for the market.

Global Antimicrobial Peptides Market - By Ailments

By ailments, the global antimicrobial peptides market is divided into Pneumonia, Hepatitis, Bacterial infections, and HIV segments. These segments represent distinct areas of application for antimicrobial peptides, which are naturally occurring molecules with potent antimicrobial properties. The market is driven by the increasing prevalence of infectious diseases and the growing demand for effective treatment options. Each segment presents unique challenges and opportunities, prompting pharmaceutical companies and researchers to explore and develop innovative peptide-based therapies to combat these specific diseases. This segmentation enables targeted approaches and tailored solutions to address the diverse healthcare needs associated with these infectious conditions.

Competitive Landscape

Global antimicrobial peptides market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S.), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in global antimicrobial peptides market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antimicrobial Peptides Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antimicrobial Peptides Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antimicrobial Peptides Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rise in infectious diseases
      • 3.2.1.2. Increasing usage of antimicrobial peptides as therapeutic agents
      • 3.2.1.3. Rising incidence of antimicrobial resistance
    • 3.2.2. Restraints
      • 3.2.2.1. High development costs
      • 3.2.2.2. Stability and formulation issues:
    • 3.2.3. Opportunities
      • 3.2.3.1. Technological advancements
      • 3.2.3.2. Rising incidence of central line-associated bloodstream infections
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory challenges
      • 3.2.4.2. Limited market awareness
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antimicrobial Peptides Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Plant
      • 4.2.1.2. Bacterial
      • 4.2.1.3. Animal
      • 4.2.1.4. Insect
    • 4.2.2. By Ailments
      • 4.2.2.1.1. Pneumonia
      • 4.2.2.1.2. Hepatitis
      • 4.2.2.1.3. Bacterial infections
      • 4.2.2.1.4. HIV
    • 4.2.3. By Distribution Channel
      • 4.2.3.1.1. Hospital
      • 4.2.3.1.2. Research Institutes
      • 4.2.3.1.3. Specialty Clinic
      • 4.2.3.1.4. Pharmacies
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Topical
      • 4.2.4.2. Subcutaneous
      • 4.2.4.3. Intravenous
    • 4.2.5. By End Use
      • 4.2.5.1. Pharma and Healthcare
      • 4.2.5.2. Agriculture Industry
      • 4.2.5.3. Biological Engineering
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Antimicrobial Peptides Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Ailments
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Route of Administration
    • 5.2.5. By End Use
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By Product
      • 5.2.6.1.2. By Ailments
      • 5.2.6.1.3. By Distribution Channel
      • 5.2.6.1.4. By Route of Administration
      • 5.2.6.1.5. By End Use
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By Product
      • 5.2.6.2.2. By Ailments
      • 5.2.6.2.3. By Distribution Channel
      • 5.2.6.2.4. By Route of Administration
      • 5.2.6.2.5. By End Use

6. Europe Antimicrobial Peptides Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Ailments
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Use
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By Product
      • 6.2.6.1.2. By Ailments
      • 6.2.6.1.3. By Distribution Channel
      • 6.2.6.1.4. By Route of Administration
      • 6.2.6.1.5. By End Use
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By Product
      • 6.2.6.2.2. By Ailments
      • 6.2.6.2.3. By Distribution Channel
      • 6.2.6.2.4. By Route of Administration
      • 6.2.6.2.5. By End Use
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By Product
      • 6.2.6.3.2. By Ailments
      • 6.2.6.3.3. By Distribution Channel
      • 6.2.6.3.4. By Route of Administration
      • 6.2.6.3.5. By End Use
      • 6.2.6.4. France
      • 6.2.6.4.1. By Product
      • 6.2.6.4.2. By Ailments
      • 6.2.6.4.3. By Distribution Channel
      • 6.2.6.4.4. By Route of Administration
      • 6.2.6.4.5. By End Use
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By Product
      • 6.2.6.5.2. By Ailments
      • 6.2.6.5.3. By Distribution Channel
      • 6.2.6.5.4. By Route of Administration
      • 6.2.6.5.5. By End Use
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By Product
      • 6.2.6.6.2. By Ailments
      • 6.2.6.6.3. By Distribution Channel
      • 6.2.6.6.4. By Route of Administration
      • 6.2.6.6.5. By End Use
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By Product
      • 6.2.6.7.2. By Ailments
      • 6.2.6.7.3. By Distribution Channel
      • 6.2.6.7.4. By Route of Administration
      • 6.2.6.7.5. By End Use
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By Product
      • 6.2.6.8.2. By Ailments
      • 6.2.6.8.3. By Distribution Channel
      • 6.2.6.8.4. By Route of Administration
      • 6.2.6.8.5. By End Use
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By Product
      • 6.2.6.9.2. By Ailments
      • 6.2.6.9.3. By Distribution Channel
      • 6.2.6.9.4. By Route of Administration
      • 6.2.6.9.5. By End Use

7. Asia Pacific Antimicrobial Peptides Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Ailments
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Use
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By Product
      • 7.2.6.1.2. By Ailments
      • 7.2.6.1.3. By Distribution Channel
      • 7.2.6.1.4. By Route of Administration
      • 7.2.6.1.5. By End Use
      • 7.2.6.2. India
      • 7.2.6.2.1. By Product
      • 7.2.6.2.2. By Ailments
      • 7.2.6.2.3. By Distribution Channel
      • 7.2.6.2.4. By Route of Administration
      • 7.2.6.2.5. By End Use
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By Product
      • 7.2.6.3.2. By Ailments
      • 7.2.6.3.3. By Distribution Channel
      • 7.2.6.3.4. By Route of Administration
      • 7.2.6.3.5. By End Use
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By Product
      • 7.2.6.4.2. By Ailments
      • 7.2.6.4.3. By Distribution Channel
      • 7.2.6.4.4. By Route of Administration
      • 7.2.6.4.5. By End Use
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By Product
      • 7.2.6.5.2. By Ailments
      • 7.2.6.5.3. By Distribution Channel
      • 7.2.6.5.4. By Route of Administration
      • 7.2.6.5.5. By End Use
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By Product
      • 7.2.6.6.2. By Ailments
      • 7.2.6.6.3. By Distribution Channel
      • 7.2.6.6.4. By Route of Administration
      • 7.2.6.6.5. By End Use
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By Product
      • 7.2.6.7.2. By Ailments
      • 7.2.6.7.3. By Distribution Channel
      • 7.2.6.7.4. By Route of Administration
      • 7.2.6.7.5. By End Use
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By Product
      • 7.2.6.8.2. By Ailments
      • 7.2.6.8.3. By Distribution Channel
      • 7.2.6.8.4. By Route of Administration
      • 7.2.6.8.5. By End Use
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By Product
      • 7.2.6.9.2. By Ailments
      • 7.2.6.9.3. By Distribution Channel
      • 7.2.6.9.4. By Route of Administration
      • 7.2.6.9.5. By End Use
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By Product
      • 7.2.6.10.2. By Ailments
      • 7.2.6.10.3. By Distribution Channel
      • 7.2.6.10.4. By Route of Administration
      • 7.2.6.10.5. By End Use

8. Latin America Antimicrobial Peptides Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Ailments
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Use
    • 8.2.6. By Country
      • 8.2.6.1. Brazil
      • 8.2.6.1.1. By Product
      • 8.2.6.1.2. By Ailments
      • 8.2.6.1.3. By Distribution Channel
      • 8.2.6.1.4. By Route of Administration
      • 8.2.6.1.5. By End Use
      • 8.2.6.2. Mexico
      • 8.2.6.2.1. By Product
      • 8.2.6.2.2. By Ailments
      • 8.2.6.2.3. By Distribution Channel
      • 8.2.6.2.4. By Route of Administration
      • 8.2.6.2.5. By End Use
      • 8.2.6.3. Argentina
      • 8.2.6.3.1. By Product
      • 8.2.6.3.2. By Ailments
      • 8.2.6.3.3. By Distribution Channel
      • 8.2.6.3.4. By Route of Administration
      • 8.2.6.3.5. By End Use
      • 8.2.6.4. Peru
      • 8.2.6.4.1. By Product
      • 8.2.6.4.2. By Ailments
      • 8.2.6.4.3. By Distribution Channel
      • 8.2.6.4.4. By Route of Administration
      • 8.2.6.4.5. By End Use
      • 8.2.6.5. Rest of LATAM
      • 8.2.6.5.1. By Product
      • 8.2.6.5.2. By Ailments
      • 8.2.6.5.3. By Distribution Channel
      • 8.2.6.5.4. By Route of Administration
      • 8.2.6.5.5. By End Use

9. Middle East and Africa Antimicrobial Peptides Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Ailments
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Use
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By Product
      • 9.2.6.1.2. By Ailments
      • 9.2.6.1.3. By Distribution Channel
      • 9.2.6.1.4. By Route of Administration
      • 9.2.6.1.5. By End Use
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By Product
      • 9.2.6.2.2. By Ailments
      • 9.2.6.2.3. By Distribution Channel
      • 9.2.6.2.4. By Route of Administration
      • 9.2.6.2.5. By End Use
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By Product
      • 9.2.6.3.2. By Ailments
      • 9.2.6.3.3. By Distribution Channel
      • 9.2.6.3.4. By Route of Administration
      • 9.2.6.3.5. By End Use
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By Product
      • 9.2.6.4.2. By Ailments
      • 9.2.6.4.3. By Distribution Channel
      • 9.2.6.4.4. By Route of Administration
      • 9.2.6.4.5. By End Use
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By Product
      • 9.2.6.5.2. By Ailments
      • 9.2.6.5.3. By Distribution Channel
      • 9.2.6.5.4. By Route of Administration
      • 9.2.6.5.5. By End Use
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By Product
      • 9.2.6.6.2. By Ailments
      • 9.2.6.6.3. By Distribution Channel
      • 9.2.6.6.4. By Route of Administration
      • 9.2.6.6.5. By End Use
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By Product
      • 9.2.6.7.2. By Ailments
      • 9.2.6.7.3. By Distribution Channel
      • 9.2.6.7.4. By Route of Administration
      • 9.2.6.7.5. By End Use
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By Product
      • 9.2.6.8.2. By Ailments
      • 9.2.6.8.3. By Distribution Channel
      • 9.2.6.8.4. By Route of Administration
      • 9.2.6.8.5. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antimicrobial Peptides Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of COVID-19 on Global Antimicrobial Peptides Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Eli Lilly and Company
  • 12.2. Pfizer Inc.
  • 12.3. GSK Group of Companies (U.S)
  • 12.4. Novartis AG
  • 12.5. EnBiotix Inc.
  • 12.6. Johnson & Johnson Private Limited
  • 12.7. Merck & Co., Inc.
  • 12.8. Alexion Pharmaceuticals, Inc.
  • 12.9. Melinta Therapeutics, LLC
  • 12.10. Vertex Pharmaceuticals Incorporated
  • 12.11. AnaSpec
  • 12.12. AMP Biotech
  • 12.13. Phoenix Biotechnology Inc.
  • 12.14. Novabiotics
  • 12.15. Ontores Biotechnologies Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations